-transparent.png){kind=logo}
Deoxycytidine kinase (dCK) is a rate-limiting enzyme for the activation of ara-C. It is responsible for the phosphorylation of ara-C which is widely used in the treatment of leukemia. We examined the effect of etoposide on dCK in L1210 cells and found that incubation with 10 microM etoposide for 1 h increased dCK activity to 170% of the control. This effect of etoposide on dCK activity was concentration-dependent up to at least 100 microM of the substance.
Related Publications
K Ooi, and
T Ohkubo, and
M Higashigawa, and
H Kawasaki, and
M Sakurai
June 1974,
Journal of cellular physiology,
K Ooi, and
T Ohkubo, and
M Higashigawa, and
H Kawasaki, and
M Sakurai
January 1992,
Oncology research,
K Ooi, and
T Ohkubo, and
M Higashigawa, and
H Kawasaki, and
M Sakurai
November 1991,
Cancer research,
K Ooi, and
T Ohkubo, and
M Higashigawa, and
H Kawasaki, and
M Sakurai
September 1968,
The Journal of biological chemistry,
K Ooi, and
T Ohkubo, and
M Higashigawa, and
H Kawasaki, and
M Sakurai
July 1993,
Biochemical and biophysical research communications,
K Ooi, and
T Ohkubo, and
M Higashigawa, and
H Kawasaki, and
M Sakurai
January 2004,
Leukemia & lymphoma,
K Ooi, and
T Ohkubo, and
M Higashigawa, and
H Kawasaki, and
M Sakurai
August 1999,
General pharmacology,
K Ooi, and
T Ohkubo, and
M Higashigawa, and
H Kawasaki, and
M Sakurai
July 2004,
Biochemical pharmacology,
K Ooi, and
T Ohkubo, and
M Higashigawa, and
H Kawasaki, and
M Sakurai
January 1989,
Leukemia research,
K Ooi, and
T Ohkubo, and
M Higashigawa, and
H Kawasaki, and
M Sakurai
July 1987,
Cancer research,
